Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen... | March 28, 2023

Related Keywords

United Kingdom ,New York ,United States ,Christopherm Calabrese ,Kevin Gardner ,Mike Beyer ,Jonothan Blackbourn ,University Of Oxford ,Hepatitisb Foundation ,Oxford University Press ,Sam Brown Inc ,Exchange Commission ,Oxford University ,Arbutus Biopharma Corporation ,Nasdaq ,Health Information For International ,Centers For Disease ,Astrazeneca ,Completed Phase ,European Association ,Bill Enright ,East Asia ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Disease Control ,Health Information ,Sci Advisors ,Lifesci Advisors ,Vaccitech Plc Stock Exchange ,News ,Information ,Press Release ,Ompleted ,Hase ,Trial ,F ,Pet ,Its ,Primary ,End ,Secondary ,Us ,The ,First ,Immunotherapy ,Hown ,O ,Conduce ,Sustained ,Reductions ,N ,Hepatitis , ,Urface Vacc Us91864c1071 ,